Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $76

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $79 to $76.

Benzinga · 11/06/2019 14:08

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $79 to $76.